Home Newsfeeds Baird Maintains Outperform on Owens & Minor, Lowers Price Target to $62

Baird Maintains Outperform on Owens & Minor, Lowers Price Target to $62

Baird analyst Eric Coldwell maintains Owens & Minor (NYSE:OMI) with a Outperform and lowers the price target from $70 to $62.

byBenzinga Newsdesk

August 4, 2022

1 minute read

Baird analyst Eric Coldwell maintains Owens & Minor (NYSE:OMI) with a Outperform and lowers the price target from $70 to $62.

Why SNDL Stock Is Rising

By Henry Khederian

August 31, 1:57 PM

SNDL Inc (NASDAQ: SNDL) shares are trading higher by 7.2% to $1.78 during Thursday's session on upward momentum and amid strength in the broader cannabis sector. Shares of cannabis stocks and ETFs are trading higher following a

SNDL

Analyst Ratings

10 Analysts Have This to Say About Accolade

By Benzinga Insights

July 1, 10:27 AM

Over the past 3 months, 10 analysts have published their opinion on Accolade (NASDAQ:ACCD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

ACCD

AstraZeneca’s Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial

By Vandana Singh

June 18, 9:22 AM

AstraZeneca announced that the CAPItello-290 Phase 3 trial for Truqap (capivasertib) combined with paclitaxel in advanced or metastatic triple-negative breast cancer did not meet primary endpoints for overall survival.

AZN